Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study

被引:79
作者
Yamamoto, Takayuki [1 ]
Shiraki, Manabu [1 ]
Bamba, Takuya [1 ]
Umegae, Satoru [1 ]
Matsumoto, Koichi [1 ]
机构
[1] Yokkaichi Social Insurance Hosp, Ctr Inflammatory Bowel Dis, Yokaichi, Mie 5100016, Japan
关键词
Calprotectin; Crohn's disease; faecal marker; lactoferrin; postoperative recurrence;
D O I
10.1177/2050640613501818
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background: Several studies have reported that faecal calprotectin and lactoferrin showed a close correlation with endoscopic inflammation in patients with inflammatory bowel disease. However, the clinical significance of faecal calprotectin or lactoferrin in postoperative Crohn's disease (CD) is not fully evaluated. This prospective study was to investigate the relationship between endoscopic activity, and faecal calprotectin and lactoferrin, and assess the predictive value of these markers for future recurrence. Methods: Twenty patients who remained in remission during 6-12 months after ileocolonic resection for CD were included. All patients underwent ileocolonoscopy for assessing endoscopic activity (Rutgeerts score) in the neo-terminal ileum. A stool sample was collected for measurement of calprotectin and lactoferrin. All patients were then followed up for 12 months, and clinical recurrence was defined as a CDAI >150 with an increase of >= 70 points. Results: The mean time between surgery and the endoscopic examination at entry was 7.2 months. The endoscopic scores were i0 or i1 in 10 patients, i2 in six patients, i3 in three patients, and i4 in one patient. Both calprotectin and lactoferrin positively correlated with the endoscopic scores (p = 0.0001 and p = 0.038, respectively). Six patients developed clinical recurrence during the 12-month follow-up. Both calprotectin and lactoferrin levels were significantly higher in patients with clinical recurrence than those in remission (p = 0.0007 and p = 0.025, respectively). A cutoff value of 170 mg/g for calprotectin had a sensitivity of 83% and a specificity of 93% to predict a risk of clinical recurrence, while a cutoff value of 140 mg/g for lactoferrin had a sensitivity of 67% and a specificity of 71%. Conclusions: Both calprotectin and lactoferrin levels correlate well with endoscopic activity after ileocolonic resection for CD. Calprotectin and lactoferrin could be clinically relevant biomarkers for predicting postoperative recurrence. Further well-designed large trials should strengthen the findings of the present investigation.
引用
收藏
页码:368 / 374
页数:7
相关论文
共 26 条
[1]
Lactoferrin: A multifunctional glycoprotein involved in the modulation of the inflammatory process [J].
Baveye, S ;
Elass, E ;
Mazurier, J ;
Spik, G ;
Legrand, D .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1999, 37 (03) :281-286
[2]
BAYNES RD, 1994, ADV EXP MED BIOL, V357, P133
[3]
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[4]
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368
[5]
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease [J].
D'Haens, Geert ;
Ferrante, Marc ;
Vermeire, Severine ;
Baert, Filip ;
Noman, Maja ;
Moortgat, Liesbeth ;
Geens, Patricia ;
Iwens, Doreen ;
Aerden, Isolde ;
Van Assche, Gert ;
Van Olmen, Gust ;
Rutgeerts, Paul .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) :2218-2224
[6]
Can calprotectin predict relapse risk in inflammatory bowel disease? [J].
D'Inca, Renata ;
Dal Pont, Elisabetta ;
Di Leo, Vincenza ;
Benazzato, Luca ;
Martinato, Matteo ;
Lamboglia, Francesca ;
Oliva, Lydia ;
Sturniolo, Giacomo Carlo .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08) :2007-2014
[7]
Postoperative recurrent luminal Crohn's Disease: A systematic review [J].
De Cruz, Peter ;
Kamm, Michael A. ;
Prideaux, Lani ;
Allen, Patrick B. ;
Desmond, Paul V. .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (04) :758-777
[8]
Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? [J].
Garcia-Sanchez, Valle ;
Iglesias-Flores, Eva ;
Gonzalez, Raul ;
Gisbert, Javier P. ;
Maria Gallardo-Valverde, Jose ;
Gonzalez-Galilea, Angel ;
Naranjo-Rodriguez, Antonio ;
de Dios-Vega, Juan F. ;
Muntane, Jordi ;
Gomez-Camacho, Federico .
JOURNAL OF CROHNS & COLITIS, 2010, 4 (02) :144-152
[9]
Fecal Calprotectin and Lactoferrin for the Prediction of Inflammatory Bowel Disease Relapse [J].
Gisbert, Javier P. ;
Bermejo, Fernando ;
Perez-Calle, Jose-Lazaro ;
Taxonera, Carlos ;
Vera, Isabel ;
McNicholl, Adrian G. ;
Algaba, Alicia ;
Lopez, Pilar ;
Lopez-Palacios, Natalia ;
Calvo, Marta ;
Gonzalez-Lama, Yago ;
Carneros, Jose-Antonio ;
Velasco, Marta ;
Mate, Jose .
INFLAMMATORY BOWEL DISEASES, 2009, 15 (08) :1190-1198
[10]
Johne B, 1997, J CLIN PATHOL-MOL PA, V50, P113